We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Providing dental professionals with an online Personal Development Plan for their Continuing Professional Development. Dentinal Tubules currently has more than 2,100 individuals registered to use the service and over 2,700 dental practice professionals that are paying for a subscription. Dentinal Tubules hosts more than 1,500 educational and certified videos to help with a professional's CPD, in addition they also offer live courses, a livestream and an annual congress. Investments will be used to enhance, develop and bring the technology in-house.
days to go: Expired investment: £155,820
A technological healthcare service allowing patients to discuss any concerns with a GP, clinician or specialists via video consultations, home visits, or appointments at the clinic. DocNoc launched less than 12 months ago and has over 160 NHS and private sector doctors and clinics registered on the service. The company's business model is easily flexible and aim to launch DocNoc internationally.
days to go: Expired investment: £269,710
Earth Broadband stands out as one of the UK's pioneering green broadband providers, revolutionizing the way people use broadband services for environmental good. Founded by Luke Chapman in 2022 after witnessing climate change effects in Indonesia, the company aims to reshape broadband services, offering wildlife-themed packages and facilitating monthly contributions to planet-saving initiatives. Using innovative AI technology, Earth Broadband enhances customer service while empowering users to contribute to environmental causes by planting trees and removing ocean plastic through their app. The company's strategy focuses on achieving large-scale impact with a small, efficient team, aiming to revolutionize broadband provision.
days to go: Expired investment: £308,580
FreeHand is a robotic surgical camera controller that aims to make surgeries precise and safer. The company cites data arguing that over 15 million keyhole surgeries are performed annually in which an additional clinician is mostly required to manually hold the camera the surgeon uses to see the operating field. The company asserts that this is not the most optimal way. FreeHand's robotic camera controller aims to solve this issue by providing steady images and precise control, saving time, and improving outcomes. The company has regulatory clearance for sale in the EU, US, and Japan. FreeHand points out that surgical robotics is one of the fastest-growing segments in Medical Technology, projected to reach $91.5 billion by 2025. It aims to become a contender in this segment. FreeHand claims that surgeons have successfully used its robotic controller in more than 15,000 procedures. The company will use the investment to expand the distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.
days to go: Expired investment: £1,003,350
An innovation event that displays the greatest in medical healthcare technologies within exhibitions, conferences and workshops. GIANT Health has over 2000 delegates registered, with 235 speakers and 33 exhibitors whilst being sponsored by 8 global companies. Current revenue streams consist of event ticket sales, partnership packages, stage demos, etc. Events are held across Europe, with international expansion in the next phase.
days to go: Expired investment: £62,770
Halo Coffee are a range of 100% compostable, biodegradable coffee capsules, containing premium quality coffees which are fully compatible with Nespresso home machines. The capsules have been designed by a world-leading environmental packaging team and are made from a natural blend of paper pulp and bamboo.     
days to go: Expired investment: £656,250
Handsome are one of the leading brands of back care stocked in over 1000 stores such as boots and CVS Pharmacy. They stock a comprehensive range of award winning products for pain relief and posture management and aim to become the leading consumer brand in back care through their brand BAC< BackPainHelp.
days to go: Expired investment: £514,530
Harvest London has produced a moving hydroponic and vertical and farm in London. It has connected a wide understanding of agriculture and technology and built a creative business. The company has created relationships with London's top chefs and restaurants and are working on the expansion. The company is planning to use the funds for miscellaneous expenses, operations and technology.
days to go: Expired investment: £402,060
Hydro Wind Energy (HWE) is developing technologies to solve global issues of low-cost clean electricity, grid-scale energy storage, and seawater desalination. Its OceanHydro Wind technology harnesses offshore altitude wind using kites, stores the energy subsea and releases it on demand as electrical energy. HWE has also developed SubSea RO Wind technology to desalinate seawater into potable freshwater. The company has developed QuenchSea, which it asserts is the world's only low-cost handheld seawater desalination device. HWE has featured in publications like Wired, Euronews, Business Insider, and Yahoo Finance. It was selected as one of the top 100 start-ups shaping the 4th Industrial Revolution by the World Economic Forum (WEF). HWE will use the investment to fund technology development, product development teams, international expansion, and scale QuenchSea globally.
days to go: Expired investment: £696,260
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go: Expired investment: £357,179
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph